Sign In
Buy GLMD
$0.621
+0.0220 (+3.67%)
At Close: Jul 31, 2026
P.a.w. Capital Corp Buys OptimizeRx Corp, Aptose Biosciences Inc, Orchard Therapeutics PLC, ...
12:00am, Tuesday, 28'th Jan 2020Madrigal: Beyond NASH
05:35pm, Tuesday, 14'th Jan 2020
After the robust Phase 2 NASH data for resmetirom, Madrigal commenced its Phase 3 trial earlier this year. There is another upcoming Phase 3 investigation to st
Is Galmed Pharmaceuticals Ltd.'s (NASDAQ:GLMD) CEO Overpaid Relative To Its Peers?
01:25pm, Friday, 03'rd Jan 2020
Allen Baharaff has been the CEO of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) since 2012. This analysis aims first to...
Do Hedge Funds Love Galmed Pharmaceuticals Ltd (GLMD)?
12:21am, Sunday, 15'th Dec 2019
Based on the fact that hedge funds have collectively under-performed the market for several years, it would be easy to assume that their stock picks simply aren't very good. However, our research show
Top Ranked Momentum Stocks to Buy for December 4th
02:26pm, Wednesday, 04'th Dec 2019
Top Ranked Momentum Stocks to Buy for December 4th
NASH Scorecard Year to Date: The Winners and the Losers
01:41pm, Friday, 29'th Nov 2019
NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.
Galmed Pharmaceuticals Ltd (GLMD) CEO Allen Baharaff on Q3 2019 Results - Earnings Call Transcript
12:00am, Sunday, 10'th Nov 2019Edited Transcript of GLMD earnings conference call or presentation 6-Nov-19 1:30pm GMT
03:57am, Saturday, 09'th Nov 2019
Q3 2019 Galmed Pharmaceuticals Ltd Earnings Call
Galmed Pharmaceuticals Provides Business Update and Reports Third Quarter 2019 Financial Results
12:00pm, Wednesday, 06'th Nov 2019
- Conference Call and Webcast Today at 8:30 a.m. EST / 5:30 a.m. PST - TEL AVIV, Israel , Nov. 6, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), ...
